01 Growing Adoption Of Digital Inhalers With Integrated Adherence Analytics The rising use of digital inhalers equipped with embedded sensors that track real-time usage patterns and inhalation technique is a key trend for market growth. These devices transmit adherence data to clinicians via connected platforms, enabling personalized treatment adjustments and early intervention for uncontrolled symptoms. This technology is reshaping asthma management by improving medication compliance, reducing exacerbations, and supporting data-driven clinical decision-making.
02 Rising Use of Pharmacogenomic Profiling for Personalized Asthma Drug Selection A key trend in the asthma therapeutics market is the integration of pharmacogenomic profiling to tailor drug selection based on a patient’s genetic response to inhaled corticosteroids, bronchodilators, or biologics. This approach enables clinicians to identify patients with steroid-resistant asthma, optimize biologic eligibility, and reduce trial-and-error prescribing. As precision medicine expands, genetic markers such as IL-4Rα variants and β2-adrenergic receptor polymorphisms are increasingly influencing individualized treatment pathways.
March 2026 AstraZeneca expanded its respiratory medicine portfolio with continued global availability and lifecycle development initiatives for biologic therapies targeting severe asthma management.
September 2025 Sanofi and Regeneron expanded access initiatives for Dupixent® (dupilumab) through additional regulatory and commercialization activities, strengthening their position in biologic treatments for severe asthma.
May 2025 GSK advanced its respiratory therapeutics pipeline through new clinical and development initiatives focused on next-generation asthma treatments and biologic therapies.